Picture of Novartis AG logo

NOVN Novartis AG News Story

0.000.00%
ch flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

Deals of the day-Mergers and acquisitions

Adds: Ecolab, Silgan and ByteDance; Updates: Unilever

March 20 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1400 GMT on Friday:

** U.S. packaging company Silgan Holdings SLGN.N has signaled interest in taking over German medical packaging maker Gerresheimer GXIG.DE, according to two sources familiar with the matter.

nL6N4080L0

** Ecolab  said it would acquire CoolIT Systems from KKR  for about $4.75 billion in cash, as the water solutions firm seeks to capitalize on surging demand for liquid cooling in data centers.

nL4N4080XL

** China's ByteDance has agreed to sell Shanghai Moonton Technology, the studio behind popular mobile game "Mobile Legends: Bang Bang," to a Riyadh-based gaming firm owned by Saudi Arabia's Public Investment Fund, the companies said.

nL1N4080DO

** U.S. consumer health products maker Prestige Consumer Healthcare  said it would buy the Breathe Right brand and other assets from Foundation Consumer Healthcare in a deal valued at $1.045 billion.

nL6N4080JQ

** Unilever  is in talks to sell its foods business to smaller rival McCormick & Company , potentially marking a major shift for the British consumer goods company as it seeks to focus on higher-growth household and personal care businesses.

nL6N4080CJ

** Talks to sell Thyssenkrupp's  steel division to India's Jindal Steel International are not making progress and the long-awaited deal must not be stalled for months, the German company's deputy supervisory board chairman said.

nL8N4080BW

** British cross-border payments processor CAB Payments  said that it has rejected the recent all-cash offer from financial services firm StoneX , saying the proposal undervalues the company and its future prospects.

nL6N4080D7

** Swiss drugmaker Novartis NOVN.S agreed to buy a breast cancer drug candidate for up to $3 billion from U.S. biotech firm Synnovation Therapeutics, adding a targeted therapy to its pipeline of cancer drugs.

nL1N40807H

 (Compiled by Rajarshi Roy and Dharna Bafna in Bengaluru)

 ((Rajarshi.Roy@thomsonreuters.com))

Recent news on Novartis AG

See all news